Biotechs Push FDA For Clear-Cut Biosimilar Labeling Rules
Several biotechnology companies told the U.S. Food and Drug Administration on Friday that while they supported its proposed regulations for biosimilar drugs, the agency needed to clarify naming, labeling and approval...To view the full article, register now.
Already a subscriber? Click here to view full article